SPIA
ALDX icon

Steward Partners Investment Advisory’s Aldeyra Therapeutics ALDX Stock Holding History

Steward Partners Investment Advisory’s Portfolio ALDX Stock Details ALDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-600
Closed -$2K – 3218
2022
Q2 		$2K Buy
+600
New +$2.06K ﹤0.01% 2975
2021
Q2 		– Sell
-1,200
Closed -$14.3K – 7077
2021
Q1 		$14.3K Buy
+1,200
New +$13.8K ﹤0.01% 2634

Other funds holding ALDX

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Verition Fund Management
Verition Fund Management Greenwich, Connecticut $15.4B AUM 30.69% 1-Year Est. Return
KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return

Steward Partners Investment Advisory's ALDX Position: Q3 2022 in Review

Steward Partners Investment Advisory sold out of Aldeyra Therapeutics (ALDX) in Q3 2022, closing a stake of 600 shares — an estimated $2K sold.

Steward Partners Investment Advisory first reported a position in ALDX in Q1 2021 and held it in 2 quarters. The position peaked at $14.3K in Q1 2021. 89 funds tracked by Wall St. Rank hold ALDX as of Q3 2022.

  • Steward Partners Investment Advisory reported no remaining Aldeyra Therapeutics position as of Q3 2022 after selling out during the quarter.
  • Steward Partners Investment Advisory sold 600 Aldeyra Therapeutics shares in Q3 2022, an estimated $2K.
  • Steward Partners Investment Advisory first reported a position in Aldeyra Therapeutics in Q1 2021 and held it in 2 quarters.
  • Steward Partners Investment Advisory's Aldeyra Therapeutics position peaked at $14.3K in Q1 2021.
  • 89 funds tracked by Wall St. Rank held Aldeyra Therapeutics as of Q3 2022.

Based on Steward Partners Investment Advisory's 13F filing for Q3 2022, filed 10 Nov 2022.